Navigation Links
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Date:10/30/2010

atment regimens," said Greg Fanning PhD, head of hepatitis C research and development at Tibotec. "TMC435 is an important component of our growing HCV pipeline and we are encouraged by the results of the interim analysis presented at the AASLD meeting."

TMC435 is also being studied in HCV genotype-1 treatment-experienced patients who have failed treatment with peg-interferon and ribavirin. The ASPIRE study (Antiviral STAT-C Protease Inhibitor Regimen in Experienced patients; TMC435-C206; NCT00980330) is an ongoing global phase 2b randomized, double-blind, placebo controlled study in 463 patients.

In addition to the late-breaker oral presentation described above, data on TMC435 has been presented in 4 posters at AASLD:

278. "In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters." M.T. Huisman

812. "Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to Therapy (OPERA)-1 study." O. Lenz

895. "A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6." C. Moreno

1873. "Pharmacokinetic-pharmacodynamic analyses of TMC435 in patients infected with Hepatitis C Virus (HCV) genotypes 2 to 6." V. Sekar

About HCV

HCV is a blood-borne infectious disease that affects the liver.(1) With an estimated 170 million people infected worldwide(1) and three to four million people newly infected each year,(2) HCV puts a significant burden on patients and society. Chronic infection with HCV can lead to liver cancer and other serious and fatal liver diseases, and is the most common cause of liver transplant worldwide.(3)  Discovering and developing new treatments is very important to improving the standard of care for the millions of people living with this disease.

About Tibotec Pharmaceuticals

Tibotec
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Topricin ... BioMedics, Inc., has been listed among nationally recommended ... an initiative conducted by "U.S. News" Health in ... earned the “No. 1 Pharmacists Recommended designation” ... other national OTC brands, and is the only ...
(Date:5/17/2013)... a world-leading provider of scientific, technical and medical information ... recent study in Reproductive BioMedicine Online ... with an abnormal chromosomal composition can be identified by ... thereby classifying the risk of genetic abnormality without a ... undertaken a retrospective study, using their predictive model to ...
(Date:5/17/2013)... 2013  Yongye International, Inc. (NASDAQ: YONG ... and distributor of crop nutrient products in ... that, on May 16, 2013, the special committee (the ... of Directors") was provided a letter (the "Letter") issued ... ) Limited ("Abax") to Full Alliance International Limited ("Full ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... ST. LOUIS, June 2 SAFC Hitech(TM), a ... Group (Nasdaq: SIAL ),today announced the introduction ... cost-efficient migration path to controlled precursor delivery,for larger ... combined,with increased safety controls., The OM700 offers ...
... expertise, SAN DIEGO, June 2 Trius ... to its Board of Directors. Truex is,the founder, ... as President and CEO of Peninsula Pharmaceuticals where ... $21000000 from a key,strategic partner) and negotiated both ...
... Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May 30 ... release earlier today, entitled,"Targeted Genetics Reports Additional Data From Inflammatory ... study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, Ph.D., ...
Cached Biology Technology:SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3Trius Appoints Paul Truex to Board of Directors 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3
(Date:5/20/2013)... A novel vaccine study from South Dakota State University ... unveiled at the American Association of Pharmaceutical Scientists, (AAPS) ... May 20 - Wednesday, May 22 at the Sheraton ... goal of a vaccine is to stimulate the immune ... disease", explained Dr. Hemachand Tummala, assistant professor of Pharmaceutical ...
(Date:5/20/2013)... of Bristol and published online today in the ... the brain and inner ear developed in dinosaurs. ... together with Tom Hbner from the Niederschsische Landesmuseum in ... old dinosaurs. , The two palaeontologists studied different fossils ... very young (juvenile) individual of approximately three years ...
(Date:5/20/2013)... Boulder, Colo., USA New Geology ... 16 May 2013 cover a wide swath of ... tectonics, oceanography, geophysics, and paleobotany. Locations studied include ... mine at Alpi Apuane, Italy; Ukraine; Mars; and ... , 1. Rubies, jadeite, and plate tectonics;, ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2Fossil brain teaser 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... for the annual infectious diseases meeting of the American ... 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Place Convention Center in Chicago, Illinois. ... new information on clinical and basic research in infectious ...
... of a natural body chemical may allow doctors to reduce ... of critically ill patients. "Infection is a common and ... ways to improve the outcomes of sick, elderly patients and, ... Heyland, a professor of Medicine at Queen,s, director of the ...
... the U.S. first responder community,s need for documentary standards ... Institute of Standards and Technology (NIST) Law Enforcement Standards ... to first responders as part of a pilot project ... will help OLES gauge whom needs access to standards ...
Cached Biology News:Finding could reduce antibiotic use in critically ill patients 2It's your standard pilot project: NIST to offer documentary standards to first responders 2
...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
... Affinity purified polyclonal antibody to the ... Goat. Isolated from a serum pool ... Salmonella. This antibody is broadly reactive ... from ATCC. It has excellent specificity ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: